Divestiture/carve-outAug 25, 2026Pending
🇺🇸 United States
STSangamo Therapeutics, Inc. Fabry disease gene therapy business (isaralgagene civaparvovec, ST-920)PTPTC Therapeutics, Inc.
Healthcare › Biotechnology
Deal valueUndisclosed
AnnouncedAug 25, 2026
ConsiderationCash
StructureOther
RegionNorth America
Cross-borderNo
Contingent paymentYes
Overview
PTC Therapeutics agreed to acquire substantially all the assets of Sangamo Therapeutics' Fabry disease gene therapy business, including ST-920, in a Chapter 11 Section 363 sale. The price includes upfront consideration and a milestone payment tied to FDA accelerated approval; the amounts are not stated.
Deal rationale
PTC seeks to acquire Sangamo's clinical-stage Fabry disease gene therapy program through a bankruptcy court-supervised sale.
AI-generated from the SEC filingPendingHealthcare › BiotechnologyUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
None listed
Sell-side
RJRaymond James
Parties
Target
STSangamo Therapeutics, Inc. Fabry disease gene therapy business (isaralgagene civaparvovec, ST-920)
- Headquarters
- United States
- Ticker
- —
Acquirer
PTPTC Therapeutics, Inc.
- Headquarters
- United States
- Ticker
- —
Seller
STSangamo Therapeutics, Inc.
- Headquarters
- —
- Ticker
- —